Section A: Submissions for registration
The committee provided advice on one application:
- provisional registration of a new vaccine for active immunisation for COVID-19 (product name Nuvaxovid; active ingredient SARS-CoV-2 rS with Matrix-M adjuvant; applicant Biocelect Pty Ltd) that had been under evaluation from February 2021.
Details of the ACV advice associated with this pre-market item has been released within the Australian Public Assessment Report (AusPAR). To browse all AusPARs see AusPAR search.
Section B: Safety
The committee was not asked to provide advice on any safety matter.
Further information
For further information on the ACV, please visit Advisory Committee on Vaccines or contact the ACV by email ACV@health.gov.au.